Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charles D. Goldman is active.

Publication


Featured researches published by Charles D. Goldman.


Journal of Clinical Oncology | 2012

Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841

Jan Franko; Qian Shi; Charles D. Goldman; Barbara A. Pockaj; Garth D. Nelson; Richard M. Goldberg; Henry C. Pitot; Axel Grothey; Steven R. Alberts; Daniel J. Sargent

PURPOSE Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a paucity of prospective survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC). We characterized outcomes of patients with pcCRC enrolled onto two prospective randomized trials of chemotherapy and contrasted that with other manifestations of mCRC (non-pcCRC). METHODS A total of 2,095 patients enrolled onto two prospective randomized trials were evaluated for overall survival (OS) and progression-free survival (PFS). A Cox proportional hazard model was used to assess the adjusted associations. RESULTS The characteristics of the pcCRC group (n = 364) were similar to those of the non-pcCRC patients in median age (63 v 61 years, P = .23), sex (57% males v 61%, P = .23), and performance status (Eastern Cooperative Oncology Group performance status 0 or 1 94% v 96%, P = .06), but differed in frequency of liver (63% v 82%, P < .001) and lung metastases (27% v 34%, P = .01). Median OS (12.7 v 17.6 months, hazard ratio [HR] = 1.3; 95% CI, 1.2 to 1.5; P < .001) and PFS (5.8 v 7.2 months, HR = 1.2; 95% CI, 1.1 to 1.3; P = .001) were shorter for pcCRC versus non-pcCRC. The unfavorable prognostic influence of pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .001; PFS: HR = 1.1, P = .02). Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment among pcCRC (HR for OS = 0.62, P = .005) and non-pcCRC patients (HR = 0.66, P < .001). CONCLUSION pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status.


World Journal of Emergency Surgery | 2010

Dissection of the left main coronary artery after blunt thoracic trauma: Case report and literature review

Mollie James; Marnix Verhofste; Cass Franklin; Greg J. Beilman; Charles D. Goldman

Blunt chest trauma is commonly encountered by surgeons and is rarely associated with cardiac injuries. The incidence of cardiac injury is rare but can be rapidly fatal, requiring prompt recognition and treatment. We review the case of a 37 year-old male who was involved in a head-on motor vehicle collision at highway speed and was found to have an isolated left main coronary artery dissection. We then review the supporting literature for evaluation of blunt cardiac injuries and the treatment options for traumatic coronary dissection.


Journal of Surgical Oncology | 2016

Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base.

John Doromal Jacob; Caitlin Hodge; Jan Franko; Christopher M. Pezzi; Charles D. Goldman; Vs Klimberg

Invasive secretory breast carcinoma (SBC) is a rare subtype of breast malignancy.


PLOS ONE | 2015

A Computer-Assisted 3D Model for Analyzing the Aggregation of Tumorigenic Cells Reveals Specialized Behaviors and Unique Cell Types that Facilitate Aggregate Coalescence

Amanda Scherer; Spencer Kuhl; Deborah Wessels; Daniel F. Lusche; Brett Hanson; Joseph Ambrose; Edward Voss; Emily Fletcher; Charles D. Goldman; David R. Soll

We have developed a 4D computer-assisted reconstruction and motion analysis system, J3D-DIAS 4.1, and applied it to the reconstruction and motion analysis of tumorigenic cells in a 3D matrix. The system is unique in that it is fast, high-resolution, acquires optical sections using DIC microscopy (hence there is no associated photoxicity), and is capable of long-term 4D reconstruction. Specifically, a z-series at 5 μm increments can be acquired in less than a minute on tissue samples embedded in a 1.5 mm thick 3D Matrigel matrix. Reconstruction can be repeated at intervals as short as every minute and continued for 30 days or longer. Images are converted to mathematical representations from which quantitative parameters can be derived. Application of this system to cancer cells from established lines and fresh tumor tissue has revealed unique behaviors and cell types not present in non-tumorigenic lines. We report here that cells from tumorigenic lines and tumors undergo rapid coalescence in 3D, mediated by specific cell types that we have named “facilitators” and “probes.” A third cell type, the “dervish”, is capable of rapid movement through the gel and does not adhere to it. These cell types have never before been described. Our data suggest that tumorigenesis in vitro is a developmental process involving coalescence facilitated by specialized cells that culminates in large hollow spheres with complex architecture. The unique effects of select monoclonal antibodies on these processes demonstrate the usefulness of the model for analyzing the mechanisms of anti-cancer drugs.


PLOS ONE | 2017

Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44

Deborah Wessels; Daniel F. Lusche; Edward Voss; Spencer Kuhl; Emma C. Buchele; Michael R. Klemme; Kanoe B. Russell; Joseph Ambrose; Benjamin A. Soll; Aaron D. Bossler; Mohammed M. Milhem; Charles D. Goldman; David R. Soll; Andrzej Slominski

Using unique computer-assisted 3D reconstruction software, it was previously demonstrated that tumorigenic cell lines derived from breast tumors, when seeded in a 3D Matrigel model, grew as clonal aggregates which, after approximately 100 hours, underwent coalescence mediated by specialized cells, eventually forming a highly structured large spheroid. Non-tumorigenic cells did not undergo coalescence. Because histological sections of melanomas forming in patients suggest that melanoma cells migrate and coalesce to form tumors, we tested whether they also underwent coalescence in a 3D Matrigel model. Melanoma cells exiting fragments of three independent melanomas or from secondary cultures derived from them, and cells from the melanoma line HTB-66, all underwent coalescence mediated by specialized cells in the 3D model. Normal melanocytes did not. However, coalescence of melanoma cells differed from that of breast-derived tumorigenic cell lines in that they 1) coalesced immediately, 2) underwent coalescence as individual cells as well as aggregates, 3) underwent coalescence far faster and 4) ultimately formed long, flat, fenestrated aggregates that were extremely dynamic. A screen of 51 purified monoclonal antibodies (mAbs) targeting cell surface-associated molecules revealed that two mAbs, anti-beta 1 integrin/(CD29) and anti-CD44, blocked melanoma cell coalescence. They also blocked coalescence of tumorigenic cells derived from a breast tumor. These results add weight to the commonality of coalescence as a characteristic of tumorigenic cells, as well as the usefulness of the 3D Matrigel model and software for both investigating the mechanisms regulating tumorigenesis and screening for potential anti-tumorigenesis mAbs.


Annals of Surgical Oncology | 2013

Survival Among Pancreaticoduodenectomy Patients Treated for Pancreatic Head Cancer <1 or 2 cm

Jan Franko; Vladimir Hugec; Tercio L. Lopes; Charles D. Goldman


The Annals of Thoracic Surgery | 2016

Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma

Jan Franko; George Voynov; Charles D. Goldman


Journal of The American College of Surgeons | 2013

Current Use and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer

Robert P. Sticca; Steven R. Alberts; Michelle R. Mahoney; Daniel J. Sargent; Lisa M. Finstuen; Garth D. Nelson; Timothy M. Husted; Jan Franko; Charles D. Goldman; Barbara A. Pockaj


Annals of Surgical Oncology | 2012

Impact of Radiation Therapy Sequence on Survival Among Patients With Resected Pancreatic Head Ductal Carcinoma

Jan Franko; Dev R. Puri; Charles D. Goldman


Journal of Clinical Oncology | 2011

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG’s phase III trials N9741 and N9841.

Jan Franko; Qian Shi; Charles D. Goldman; Barbara A. Pockaj; Garth D. Nelson; Richard M. Goldberg; Henry C. Pitot; Axel Grothey; Steven R. Alberts; Daniel J. Sargent

Collaboration


Dive into the Charles D. Goldman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Axel Grothey

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Henry C. Pitot

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge